Citadel Advisors
RDHL

Citadel Advisors’s Redhill Biopharma RDHL Stock Holding History

Citadel Advisors’s Portfolio RDHL Stock Details RDHL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-23
Closed -$295 – 15074
2023
Q3 		$295 Hold
23
– – ﹤0.01% 14094
2023
Q2 		$699 Buy
+23
New +$1.33K ﹤0.01% 14061
2023
Q1 		– Sell
-55
Closed -$7.65K – 15374
2022
Q4 		$7.65K Buy
55
+12
+28% +$5.2K ﹤0.01% 13810
2022
Q3 		$21K Sell
43
-2
-4% -$1.74K ﹤0.01% 12062
2022
Q2 		$39K Sell
45
-17
-27% -$23.3K ﹤0.01% 12079
2022
Q1 		$155K Sell
62
-30
-33% -$71.1K ﹤0.01% 11825
2021
Q4 		$238K Sell
92
-63
-41% -$252K ﹤0.01% 11474
2021
Q3 		$712K Buy
155
+53
+52% +$360K ﹤0.01% 9024
2021
Q2 		$700K Buy
102
+45
+79% +$311K ﹤0.01% 9244
2021
Q1 		$419K Sell
57
-57
-50% -$478K ﹤0.01% 10070
2020
Q4 		$919K Buy
114
+38
+50% +$342K ﹤0.01% 6974
2020
Q3 		$780K Buy
76
+39
+105% +$320K ﹤0.01% 6482
2020
Q2 		$247K Buy
+37
New +$255K ﹤0.01% 8230
2019
Q4 		– Sell
-17
Closed -$116K – 9638
2019
Q3 		$116K Buy
+17
New +$124K ﹤0.01% 8417

Other funds holding RDHL

YAG
Yorkville Advisors Global Mountainside, New Jersey $155M AUM 58.46% 1-Year Est. Return
GS
Gagnon Securities New York $433M AUM 29.08% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
SG
StoneX Group New York $1.86B AUM 21.3% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
YAL
Your Advocates Ltd Houston, Texas $328M AUM 19.81% 1-Year Est. Return

Citadel Advisors's RDHL Position: Q1 2026 in Review

Citadel Advisors increased its Redhill Biopharma (RDHL) stake by 34% in Q1 2026, buying an estimated $5.48K and bringing the position to 20,673 shares worth $15.4K. The position accounts for ﹤0.01% of the portfolio, ranked #12712.

Citadel Advisors first reported a position in RDHL in Q4 2017 and has held it in 15 quarters since. The position peaked at $265K in Q4 2021. 16 funds tracked by Wall St. Rank hold RDHL as of Q1 2026.

  • Citadel Advisors held 20,673 shares of Redhill Biopharma worth $15.4K as of Q1 2026.
  • Citadel Advisors bought 5,196 Redhill Biopharma shares in Q1 2026, an estimated $5.48K.
  • Redhill Biopharma made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #12712 holding.
  • Citadel Advisors first reported a position in Redhill Biopharma in Q4 2017 and has held it in 15 quarters since.
  • Citadel Advisors's Redhill Biopharma position peaked at $265K in Q4 2021.
  • 16 funds tracked by Wall St. Rank held Redhill Biopharma as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.